{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.3"},{"groupId":"OG001","value":"14.5"},{"groupId":"OG002","value":"21.3"}]}],"title":"Nausea, Baseline (n=166,166,150)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.0"},{"groupId":"OG001","value":"36.0"},{"groupId":"OG002","value":"52.6"}]}],"title":"Nausea, Cycle 1 Day 8 (n=121,114,95)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.2"},{"groupId":"OG001","value":"20.5"},{"groupId":"OG002","value":"36.2"}]}],"title":"Nausea, Cycle 2 Day 1 (n=147,151,138)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.2"},{"groupId":"OG001","value":"28.1"},{"groupId":"OG002","value":"45.7"}]}],"title":"Nausea, Cycle 2 Day 8 (n=122,121,105)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"173"},{"groupId":"OG001","value":"171"},{"groupId":"OG002","value":"154"}],"units":"Participants"}],"description":"The FACT-C is a self-reported instrument which measures HRQOL pertaining to colorectal cancer. Response options on each question may range from 0 (not at all) to 4 (very much). The percentage of participants with nausea was calculated using following formula: \\[number of participants with any level of either symptom divided by the number analyzed\\] multiplied by 100.","groups":[{"description":"Participants received trastuzumab plus either docetaxel or paclitaxel. The regimen was chosen at the investigator's discretion. Option 1: trastuzumab 8 mg/kg via IV infusion on Day 1 of Cycle 1, then 6 mg/kg IV on Day 1 of each subsequent 3-week cycle; plus a minimum of 6 cycles with docetaxel 75 or 100 mg/m\\^2 IV on Day 1 of each 3-week cycle. Option 2: trastuzumab 4 mg/kg IV on Day 1 of Cycle 1, then 2 mg/kg IV weekly beginning on Day 8 of Cycle 1; plus a minimum of 18 weeks with paclitaxel 80 mg/m\\^2 IV weekly. Treatment continued until disease progression, unacceptable toxicity, or study termination. If trastuzumab or docetaxel were discontinued for toxicity, the other agent could be continued as monotherapy.","id":"OG000","title":"Trastuzumab + Taxane"},{"description":"Participants received trastuzumab emtansine plus pertuzumab-placebo. Trastuzumab emtansine was administered as 3.6 mg/kg via IV infusion, following completion of the placebo IV infusion, on Day 1 of each 3-week cycle. Treatment continued until disease progression, unacceptable toxicity, or study termination.","id":"OG001","title":"Trastuzumab Emtansine + Placebo"},{"description":"Participants received trastuzumab emtansine plus pertuzumab. Trastuzumab emtansine was administered as 3.6 mg/kg via IV infusion, following completion of the pertuzumab IV infusion, on Day 1 of each 3-week cycle. Pertuzumab was given as 840 mg IV on Day 1 of Cycle 1, then 420 mg IV on Day 1 of each subsequent 3-week cycle. Treatment continued until disease progression, unacceptable toxicity, or study termination.","id":"OG002","title":"Trastuzumab Emtansine + Pertuzumab"}],"paramType":"NUMBER","populationDescription":"ITT Population (Protocol Amendment C Subpopulation). Only participants with a FACT-C score at the designated visit (n) were included in the analysis.","reportingStatus":"POSTED","timeFrame":"At Baseline, Day 8 of Cycle 1, and Days 1 and 8 of Cycle 2","title":"Percentage of Participants Reporting Nausea According to the Relevant Single Items of The FACT Colorectal Cancel (FACT-C) Module","type":"SECONDARY","unitOfMeasure":"percentage of participants"}